Skip to main content
SpringerLink
Log in
Book cover

Bile Acids and Their Receptors pp 237–264Cite as

UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications

  • Chapter
  • First Online:

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 256))

Abstract

Bile acids (BAs) are key molecules in generating bile flow, which is an essential function of the liver. In the last decades, there have been great advances in the understanding of BA physiology, and new insights have emerged regarding the role of BAs in determining cell damage and death in several liver diseases. This new knowledge has helped to better delineate the pathophysiology of cholestasis and the adaptive responses of hepatocytes to cholestatic liver injury as well as of the mechanisms of injury of biliary epithelia. In this context, therapeutic approaches for liver diseases using hydrophilic BA (i.e., ursodeoxycholic acid, tauroursodeoxycholic, and, more recently, norursodeoxycholic acid), have been revamped. In the present review, we summarize current experimental and clinical data regarding these BAs and its role in the treatment of certain liver diseases.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Abdelkader NF, Safar MM, Salem HA (2016) Ursodeoxycholic acid ameliorates apoptotic cascade in the rotenone model of Parkinson’s disease: modulation of mitochondrial perturbations. Mol Neurobiol 53(2):810–817

    Article  CAS  PubMed  Google Scholar 

  • Ali AH, Tabibian JH, Lindor KD (2017) Update on pharmacotherapies for cholestatic liver disease. Hepatol Commun 1(1):7–17

    Article  PubMed  Google Scholar 

  • Amaral JD, Viana RJ, Ramalho RM, Steer CJ, Rodrigues CM (2009) Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res 50(9):1721–1734

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Arab JP, Cabrera D, Arrese M (2017a) Bile acids in cholestasis and its treatment. Ann Hepatol 16(Suppl. 1: s3–105):s53–s57

    Article  CAS  PubMed  Google Scholar 

  • Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M (2017b) Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Hepatology 65(1):350–362

    Article  PubMed  Google Scholar 

  • Arrese M, Karpen SJ (2010) Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases. Clin Pharmacol Ther 87(4):473–478

    Article  CAS  PubMed  Google Scholar 

  • Arrese M, Reyes H (2006) Intrahepatic cholestasis of pregnancy: a past and present riddle. Ann Hepatol 5(3):202–205

    Article  PubMed  Google Scholar 

  • Arrese M, Trauner M (2003) Molecular aspects of bile formation and cholestasis. Trends Mol Med 9(12):558–564

    Article  CAS  PubMed  Google Scholar 

  • Arrese M, Macias RI, Briz O, Perez MJ, Marin JJ (2008) Molecular pathogenesis of intrahepatic cholestasis of pregnancy. Expert Rev Mol Med 10:e9

    Article  PubMed  Google Scholar 

  • Ashby K, Navarro Almario EE, Tong W, Borlak J, Mehta R, Chen M (2018) Review article: therapeutic bile acids and the risks for hepatotoxicity. Aliment Pharmacol Ther 47(12):1623–1638

    Article  CAS  PubMed  Google Scholar 

  • Assis DN, Debray D (2017) Gallbladder and bile duct disease in Cystic Fibrosis. J Cyst Fibros 16(Suppl 2):S62–S69

    Article  PubMed  Google Scholar 

  • Azzaroli F, Mehal W, Soroka CJ, Wang L, Lee J, Crispe IN et al (2002) Ursodeoxycholic acid diminishes Fas-ligand-induced apoptosis in mouse hepatocytes. Hepatology 36(1):49–54

    Article  CAS  PubMed  Google Scholar 

  • Bacq Y, Sentilhes L, Reyes HB, Glantz A, Kondrackiene J, Binder T et al (2012) Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis. Gastroenterology 143(6):1492–1501

    Article  CAS  PubMed  Google Scholar 

  • Bacq Y, le Besco M, Lecuyer AI, Gendrot C, Potin J, Andres CR et al (2017) Ursodeoxycholic acid therapy in intrahepatic cholestasis of pregnancy: results in real-world conditions and factors predictive of response to treatment. Dig Liver Dis 49(1):63–69

    Article  CAS  PubMed  Google Scholar 

  • Baker A, Kerkar N, Todorova L, Kamath BM, Houwen RHJ (2019) Systematic review of progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol 43(1):20–36

    Article  PubMed  Google Scholar 

  • Banales JM, Huebert RC, Karlsen T, Strazzabosco M, LaRusso NF, Gores GJ (2019) Cholangiocyte pathobiology. Nat Rev Gastroenterol Hepatol. https://doi.org/10.1038/s41575-019-0125-y

    Article  Google Scholar 

  • Bell GD, Whitney B, Dowling RH (1972) Gallstone dissolution in man using chenodeoxycholic acid. Lancet 2(7789):1213–1216

    Article  CAS  PubMed  Google Scholar 

  • Benz C, Angermuller S, Tox U, Kloters-Plachky P, Riedel HD, Sauer P et al (1998) Effect of tauroursodeoxycholic acid on bile-acid-induced apoptosis and cytolysis in rat hepatocytes. J Hepatol 28(1):99–106

    Article  CAS  PubMed  Google Scholar 

  • Beuers U (2006) Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 3(6):318–328

    Article  CAS  PubMed  Google Scholar 

  • Beuers U, Spengler U, Zwiebel FM, Pauletzki J, Fischer S, Paumgartner G (1992) Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease. Hepatology 15(4):603–608

    Article  CAS  PubMed  Google Scholar 

  • Beuers U, Nathanson MH, Isales CM, Boyer JL (1993a) Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis. J Clin Invest 92(6):2984–2993

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Beuers U, Nathanson MH, Boyer JL (1993b) Effects of tauroursodeoxycholic acid on cytosolic Ca2+ signals in isolated rat hepatocytes. Gastroenterology 104(2):604–612

    Article  CAS  PubMed  Google Scholar 

  • Beuers U, Throckmorton DC, Anderson MS, Isales CM, Thasler W, Kullak-Ublick GA et al (1996) Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes. Gastroenterology 110(5):1553–1563

    Article  CAS  PubMed  Google Scholar 

  • Beuers U, Boyer JL, Paumgartner G (1998) Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications. Hepatology 28(6):1449–1453

    Article  CAS  PubMed  Google Scholar 

  • Beuers U, Bilzer M, Chittattu A, Kullak-Ublick GA, Keppler D, Paumgartner G et al (2001) Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. Hepatology 33(5):1206–1216

    Article  CAS  PubMed  Google Scholar 

  • Beuers U, Trauner M, Jansen P, Poupon R (2015a) New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol 62(1 Suppl):S25–S37

    Article  CAS  PubMed  Google Scholar 

  • Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K et al (2015b) Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’. Hepatology 62(5):1620–1622

    Article  PubMed  Google Scholar 

  • Bicocca MJ, Sperling JD, Chauhan SP (2018) Intrahepatic cholestasis of pregnancy: review of six national and regional guidelines. Eur J Obstet Gynecol Reprod Biol 231:180–187

    Article  PubMed  Google Scholar 

  • Blitzer BL, Boyer JL (1982) Cellular mechanisms of bile formation. Gastroenterology 82(2):346–357

    Article  CAS  PubMed  Google Scholar 

  • Buko VU, Lukivskaya OY, Naruta EE, Belonovskaya EB, Tauschel HD (2014) Protective effects of norursodeoxycholic acid versus ursodeoxycholic acid on thioacetamide-induced rat liver fibrosis. J Clin Exp Hepatol 4(4):293–301

    Article  PubMed  PubMed Central  Google Scholar 

  • Cai SY, Ouyang X, Chen Y, Soroka CJ, Wang J, Mennone A et al (2017) Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response. JCI Insight 2(5):e90780

    Article  PubMed  PubMed Central  Google Scholar 

  • Carey MC (1984) Bile acids and bile salts: ionization and solubility properties. Hepatology 4(5 Suppl):66S–71S

    Article  CAS  PubMed  Google Scholar 

  • Castro-Caldas M, Carvalho AN, Rodrigues E, Henderson CJ, Wolf CR, Rodrigues CM et al (2012) Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson’s disease. Mol Neurobiol 46(2):475–486

    Article  CAS  PubMed  Google Scholar 

  • Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M et al (2018) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67(1):328–357

    Article  PubMed  Google Scholar 

  • Chazouilleres O (2017) 24-Norursodeoxycholic acid in patients with primary sclerosing cholangitis: a new “urso saga” on the horizon? J Hepatol 67(3):446–447

    Article  PubMed  Google Scholar 

  • Cheng K, Ashby D, Smyth RL (2017) Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev 9:CD000222

    PubMed  Google Scholar 

  • Cheung AC, Lorenzo Pisarello MJ, LaRusso NF (2017) Pathobiology of biliary epithelia. Biochim Biophys Acta Mol Basis Dis 1864(4 Pt B):1220–1231

    PubMed  Google Scholar 

  • Coleman R (1987) Biochemistry of bile secretion. Biochem J 244(2):249–261

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Crosignani A, Setchell KD, Invernizzi P, Larghi A, Rodrigues CM, Podda M (1996) Clinical pharmacokinetics of therapeutic bile acids. Clin Pharmacokinet 30(5):333–358

    Article  CAS  PubMed  Google Scholar 

  • D’Agnolo HM, Kievit W, Takkenberg RB, Riano I, Bujanda L, Neijenhuis MK et al (2016) Ursodeoxycholic acid in advanced polycystic liver disease: a phase 2 multicenter randomized controlled trial. J Hepatol 65(3):601–607

    Article  PubMed  CAS  Google Scholar 

  • Danzinger RG, Hofmann AF, Schoenfield LJ, Thistle JL (1972) Dissolution of cholesterol gallstones by chenodeoxycholic acid. N Engl J Med 286(1):1–8

    Article  CAS  PubMed  Google Scholar 

  • Dilger K, Hohenester S, Winkler-Budenhofer U, Bastiaansen BA, Schaap FG, Rust C et al (2012) Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health. J Hepatol 57(1):133–140

    Article  CAS  PubMed  Google Scholar 

  • Elia AE, Lalli S, Monsurro MR, Sagnelli A, Taiello AC, Reggiori B et al (2016) Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol 23(1):45–52

    Article  CAS  PubMed  Google Scholar 

  • European Association for the Study of the Liver (2016) EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol 65(1):146–181

    Article  Google Scholar 

  • European Association for the Study of the Liver (2017) European Association for the Study of the L. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 67(1):145–172

    Article  Google Scholar 

  • Fabris L, Spirli C, Cadamuro M, Fiorotto R, Strazzabosco M (2017) Emerging concepts in biliary repair and fibrosis. Am J Physiol Gastrointest Liver Physiol 313(2):G102–GG16

    Article  PubMed  PubMed Central  Google Scholar 

  • Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Pojer C, Zenz R et al (2001) Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology 121(1):170–183

    Article  CAS  PubMed  Google Scholar 

  • Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O et al (2006) 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 130(2):465–481

    Article  CAS  PubMed  Google Scholar 

  • Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Farkkila M et al (2017) norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol 67(3):549–558

    Article  CAS  PubMed  Google Scholar 

  • Fiorotto R, Spirli C, Fabris L, Cadamuro M, Okolicsanyi L, Strazzabosco M (2007) Ursodeoxycholic acid stimulates cholangiocyte fluid secretion in mice via CFTR-dependent ATP secretion. Gastroenterology 133(5):1603–1613

    Article  CAS  PubMed  Google Scholar 

  • Goulis J, Leandro G, Burroughs AK (1999) Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 354(9184):1053–1060

    Article  CAS  PubMed  Google Scholar 

  • Guldutuna S, Zimmer G, Imhof M, Bhatti S, You T, Leuschner U (1993) Molecular aspects of membrane stabilization by ursodeoxycholate [see comment]. Gastroenterology 104(6):1736–1744

    Article  CAS  PubMed  Google Scholar 

  • Guzman HM, Sepulveda M, Rosso N, San Martin A, Guzman F, Guzman HC (2019) Incidence and risk factors for cholelithiasis after bariatric surgery. Obes Surg. https://doi.org/10.1007/s11695-019-03760-4

    Article  PubMed  Google Scholar 

  • Halilbasic E, Fiorotto R, Fickert P, Marschall HU, Moustafa T, Spirli C et al (2009) Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2−/− mice. Hepatology 49(6):1972–1981

    Article  CAS  PubMed  Google Scholar 

  • Halilbasic E, Claudel T, Trauner M (2013) Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol 58(1):155–168

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Halilbasic E, Steinacher D, Trauner M (2017) Nor-ursodeoxycholic acid as a novel therapeutic approach for cholestatic and metabolic liver diseases. Dig Dis 35(3):288–292

    Article  PubMed  Google Scholar 

  • Han Y, Glaser S, Meng F, Francis H, Marzioni M, McDaniel K et al (2013) Recent advances in the morphological and functional heterogeneity of the biliary epithelium. Exp Biol Med 238(5):549–565

    Article  CAS  Google Scholar 

  • Harms MH, van Buuren HR, Corpechot C, Thorburn D, Janssen HLA, Lindor KD et al (2019) Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol. https://doi.org/10.1016/j.jhep.2019.04.001

    Article  CAS  PubMed  Google Scholar 

  • Haussinger D, Kordes C (2017) Mechanisms of tauroursodeoxycholate-mediated hepatoprotection. Dig Dis 35(3):224–231

    Article  PubMed  Google Scholar 

  • Hegade VS, Speight RA, Etherington RE, Jones DE (2016) Novel bile acid therapeutics for the treatment of chronic liver diseases. Ther Adv Gastroenterol 9(3):376–391

    Article  CAS  Google Scholar 

  • Hofmann A (2009) Bile acids and the enterohepatic circulation. In: Arias IM (ed) The liver: biology and pathobiology. Kluwer, Boston, pp 287–304

    Chapter  Google Scholar 

  • Hofmann AF, Hagey LR (2008) Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci 65(16):2461–2483

    Article  CAS  PubMed  Google Scholar 

  • Hofmann AF, Hagey LR (2014) Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades. J Lipid Res 55(8):1553–1595

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hofmann AF, Small DM (1967) Detergent properties of bile salts: correlation with physiological function. Annu Rev Med 18:333–376

    Article  CAS  PubMed  Google Scholar 

  • Hofmann AF, Zakko SF, Lira M, Clerici C, Hagey LR, Lambert KK et al (2005) Novel biotransformation and physiological properties of norursodeoxycholic acid in humans. Hepatology 42(6):1391–1398

    Article  CAS  PubMed  Google Scholar 

  • Hohenester S, Wenniger LM, Paulusma CC, van Vliet SJ, Jefferson DM, Elferink RP et al (2012) A biliary HCO3-umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology 55(1):173–183

    Article  CAS  PubMed  Google Scholar 

  • Invernizzi P, Setchell KD, Crosignani A, Battezzati PM, Larghi A, O’Connell NC et al (1999) Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis. Hepatology 29(2):320–327

    Article  CAS  PubMed  Google Scholar 

  • Jansen PL, Schaap FG, Beuers UH (2012) Fibroblast growth factor 19, an anticholestatic drug produced by human liver. Gastroenterology 142(3):e29–e30

    Article  PubMed  Google Scholar 

  • Jansen PL, Ghallab A, Vartak N, Reif R, Schaap FG, Hampe J et al (2017) The ascending pathophysiology of cholestatic liver disease. Hepatology 65(2):722–738

    Article  CAS  PubMed  Google Scholar 

  • Jones H, Alpini G, Francis H (2015) Bile acid signaling and biliary functions. Acta Pharm Sin B 5(2):123–128

    Article  PubMed  PubMed Central  Google Scholar 

  • Kim DJ, Yoon S, Ji SC, Yang J, Kim YK, Lee S et al (2018) Ursodeoxycholic acid improves liver function via phenylalanine/tyrosine pathway and microbiome remodelling in patients with liver dysfunction. Sci Rep 8(1):11874

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Kitani K, Kanai S (1981) Biliary transport maximum of tauroursodeoxycholate is twice as high as that of taurocholate in the rat. Life Sci 29(3):269–275

    Article  CAS  PubMed  Google Scholar 

  • Kitani K, Kanai S (1982) Effect of ursodeoxycholate on the bile flow in the rat. Life Sci 31(18):1973–1985

    Article  CAS  PubMed  Google Scholar 

  • Kummen M, Holm K, Anmarkrud JA, Nygard S, Vesterhus M, Hoivik ML et al (2017) The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut 66(4):611–619

    Article  PubMed  Google Scholar 

  • Kurz AK, Graf D, Schmitt M, Vom Dahl S, Haussinger D (2001) Tauroursodesoxycholate-induced choleresis involves p38(MAPK) activation and translocation of the bile salt export pump in rats. Gastroenterology 121(2):407–419

    Article  CAS  PubMed  Google Scholar 

  • Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL et al (2014) Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 147(6):1338–1349 e5. quiz e15

    Article  CAS  PubMed  Google Scholar 

  • Lanzini A, De Tavonatti MG, Panarotto B, Scalia S, Mora A, Benini F et al (2003) Intestinal absorption of the bile acid analogue 75Se-homocholic acid-taurine is increased in primary biliary cirrhosis, and reverts to normal during ursodeoxycholic acid administration. Gut 52(9):1371–1375

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lazaridis KN, Gores GJ, Lindor KD (2001) Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’. J Hepatol 35(1):134–146

    Article  CAS  PubMed  Google Scholar 

  • Leuschner U, Kurtz W (1987) Treatment of primary biliary cirrhosis and cholestatic disorders with ursodeoxycholic acid. Lancet 2(8557):508

    Article  CAS  PubMed  Google Scholar 

  • Leuschner U, Leuschner M, Sieratzki J, Kurtz W, Hubner K (1985) Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study. Dig Dis Sci 30(7):642–649

    Article  CAS  PubMed  Google Scholar 

  • Li Y, Lu LG (2018) Therapeutic roles of bile acid signaling in chronic liver diseases. J Clin Transl Hepatol 6(4):425–430

    Article  PubMed  PubMed Central  Google Scholar 

  • Li S, Tan HY, Wang N, Hong M, Li L, Cheung F et al (2016) Substitutes for bear bile for the treatment of liver diseases: research progress and future perspective. Evid Based Complement Alternat Med 2016:4305074

    PubMed  PubMed Central  Google Scholar 

  • Li M, Cai SY, Boyer JL (2017a) Mechanisms of bile acid mediated inflammation in the liver. Mol Asp Med 56:45–53

    Article  CAS  Google Scholar 

  • Li Y, Tang R, Leung PSC, Gershwin ME, Ma X (2017b) Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases. Autoimmun Rev 16(9):885–896

    Article  CAS  PubMed  Google Scholar 

  • Li Q, Dutta A, Kresge C, Bugde A, Feranchak AP (2018) Bile acids stimulate cholangiocyte fluid secretion by activation of transmembrane member 16A Cl(−) channels. Hepatology 68(1):187–199

    Article  CAS  PubMed  Google Scholar 

  • Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA et al (1994) Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 106(5):1284–1290

    Article  CAS  PubMed  Google Scholar 

  • Lindor KD, Kowdley KV, Harrison ME, American College of G (2015) ACG clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol 110(5):646–659. quiz 60

    Article  CAS  PubMed  Google Scholar 

  • Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M (2019) Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology 69(1):394–419

    PubMed  Google Scholar 

  • Ma H, Zeng M, Han Y, Yan H, Tang H, Sheng J et al (2016) A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis. Medicine (Baltimore) 95(47):e5391

    Article  CAS  Google Scholar 

  • Magouliotis DE, Tasiopoulou VS, Svokos AA, Svokos KA, Chatedaki C, Sioka E et al (2017) Ursodeoxycholic acid in the prevention of gallstone formation after bariatric surgery: an updated systematic review and meta-analysis. Obes Surg 27(11):3021–3030

    Article  PubMed  Google Scholar 

  • Makino I, Tanaka H (1998) From a choleretic to an immunomodulator: historical review of ursodeoxycholic acid as a medicament. J Gastroenterol Hepatol 13(6):659–664

    Article  CAS  PubMed  Google Scholar 

  • Marin JJ, Macias RI, Briz O, Banales JM, Monte MJ (2015) Bile acids in physiology, pathology and pharmacology. Curr Drug Metab 17(1):4–29

    Article  PubMed  CAS  Google Scholar 

  • Mariotti V, Strazzabosco M, Fabris L, Calvisi DF (2018) Animal models of biliary injury and altered bile acid metabolism. Biochim Biophys Acta Mol basis Dis 1864(4 Pt B):1254–1261

    Article  CAS  PubMed  Google Scholar 

  • Mariotti V, Cadamuro M, Spirli C, Fiorotto R, Strazzabosco M, Fabris L (2019) Animal models of cholestasis: an update on inflammatory cholangiopathies. Biochim Biophys Acta Mol basis Dis 1865(5):954–964

    Article  CAS  PubMed  Google Scholar 

  • Matsubara T, Li F, Gonzalez FJ (2013) FXR signaling in the enterohepatic system. Mol Cell Endocrinol 368(1–2):17–29

    Article  CAS  PubMed  Google Scholar 

  • Mijayi K, Akiyama T, Ito M, Urakawa T, Shimaji Y (1976) The effect of ursodeoxycholic acid on liver functions in patients with chronic liver disease. A double blind study in one institution and the study on the effect on hepatic blood flow. Rinsho Kenkyu 53:1395–1403

    Google Scholar 

  • Mitsuyoshi H, Nakashima T, Sumida Y, Yoh T, Nakajima Y, Ishikawa H et al (1999) Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem Biophys Res Commun 263(2):537–542

    Article  CAS  PubMed  Google Scholar 

  • Miura T, Ouchida R, Yoshikawa N, Okamoto K, Makino Y, Nakamura T et al (2001) Functional modulation of the glucocorticoid receptor and suppression of NF-kappaB-dependent transcription by ursodeoxycholic acid. J Biol Chem 276(50):47371–47378

    Article  CAS  PubMed  Google Scholar 

  • Mok HY, Bell GD, Dowling RH (1974) Effect of different doses of chenodeoxycholic acid on bile-lipid composition and on frequency of side-effects in patients with gallstones. Lancet 2(7875):253–257

    Article  CAS  PubMed  Google Scholar 

  • Monte MJ, Marin JJ, Antelo A, Vazquez-Tato J (2009) Bile acids: chemistry, physiology, and pathophysiology. World J Gastroenterol 15(7):804–816

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Munoz-Garrido P, Marin JJ, Perugorria MJ, Urribarri AD, Erice O, Saez E et al (2015) Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. J Hepatol 63(4):952–961

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO et al (2006) Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313(5790):1137–1140

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Palma J, Reyes H, Ribalta J, Hernandez I, Sandoval L, Almuna R et al (1997) Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J Hepatol 27(6):1022–1028

    Article  CAS  PubMed  Google Scholar 

  • Pares A, Caballeria L, Rodes J, Bruguera M, Rodrigo L, Garcia-Plaza A et al (2000) Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 32(4):561–566

    Article  CAS  PubMed  Google Scholar 

  • Paumgartner G, Beuers U (2004) Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis 8(1):67–81, vi

    Article  PubMed  Google Scholar 

  • Paumgartner G, Pauletzki J, Sackmann M (1994) Ursodeoxycholic acid treatment of cholesterol gallstone disease. Scand J Gastroenterol Suppl 204:27–31

    Article  CAS  PubMed  Google Scholar 

  • Pearson T, Caporaso JG, Yellowhair M, Bokulich NA, Padi M, Roe DJ et al (2019) Effects of ursodeoxycholic acid on the gut microbiome and colorectal adenoma development. Cancer Med 8(2):617–628

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Perez MJ, Briz O (2009) Bile-acid-induced cell injury and protection. World J Gastroenterol 15(14):1677–1689

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Portincasa P, Ciaula AD, Bonfrate L, Wang DQ (2012) Therapy of gallstone disease: what it was, what it is, what it will be. World J Gastrointest Pharmacol Ther 3(2):7–20

    Article  PubMed  PubMed Central  Google Scholar 

  • Poupon R (2012) Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 36(Suppl 1):S3–S12

    Article  CAS  PubMed  Google Scholar 

  • Poupon R, Chretien Y, Poupon RE, Ballet F, Calmus Y, Darnis F (1987) Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1(8537):834–836

    Article  CAS  PubMed  Google Scholar 

  • Poupon RE, Balkau B, Eschwege E, Poupon R (1991) A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 324(22):1548–1554

    Article  CAS  PubMed  Google Scholar 

  • Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ (1997) Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 113(3):884–890

    Article  CAS  PubMed  Google Scholar 

  • Prieto J, Qian C, Garcia N, Diez J, Medina JF (1993) Abnormal expression of anion exchanger genes in primary biliary cirrhosis. Gastroenterology 105(2):572–578

    Article  CAS  PubMed  Google Scholar 

  • Prieto J, Garcia N, Marti-Climent JM, Penuelas I, Richter JA, Medina JF (1999) Assessment of biliary bicarbonate secretion in humans by positron emission tomography. Gastroenterology 117(1):167–172

    Article  CAS  PubMed  Google Scholar 

  • Quigley EM (2016) Primary biliary cirrhosis and the microbiome. Semin Liver Dis 36(4):349–353

    Article  CAS  PubMed  Google Scholar 

  • Rodrigues CM, Steer CJ (2001) The therapeutic effects of ursodeoxycholic acid as an anti-apoptotic agent. Expert Opin Investig Drugs 10(7):1243–1253

    Article  CAS  PubMed  Google Scholar 

  • Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ (1998a) A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 101(12):2790–2799

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rodrigues CM, Fan G, Wong PY, Kren BT, Steer CJ (1998b) Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med 4(3):165–178

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rodrigues CM, Ma X, Linehan-Stieers C, Fan G, Kren BT, Steer CJ (1999) Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation. Cell Death Differ 6(9):842–854

    Article  CAS  PubMed  Google Scholar 

  • Rodrigues PM, Perugorria MJ, Santos-Laso A, Bujanda L, Beuers U, Banales JM (2018) Primary biliary cholangitis: a tale of epigenetically-induced secretory failure? J Hepatol 69(6):1371–1383

    Article  CAS  PubMed  Google Scholar 

  • Roma MG, Toledo FD, Boaglio AC, Basiglio CL, Crocenzi FA, Sanchez Pozzi EJ (2011) Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. Clin Sci (Lond) 121(12):523–544

    Article  CAS  Google Scholar 

  • Rost D, Rudolph G, Kloeters-Plachky P, Stiehl A (2004) Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology 40(3):693–698

    Article  CAS  PubMed  Google Scholar 

  • Russell DW (2009) Fifty years of advances in bile acid synthesis and metabolism. J Lipid Res 50(Suppl):S120–S125

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Ruutu T, Juvonen E, Remberger M, Remes K, Volin L, Mattsson J et al (2014) Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. Biol Blood Marrow Transplant 20(1):135–138

    Article  CAS  PubMed  Google Scholar 

  • Saffioti F, Gurusamy KS, Eusebi LH, Tsochatzis E, Davidson BR, Thorburn D (2017) Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis. Cochrane Database Syst Rev 3:CD011648

    PubMed  Google Scholar 

  • Sakiani S, Kleiner DE, Heller T, Koh C (2019) Hepatic manifestations of cystic fibrosis. Clin Liver Dis 23(2):263–277

    Article  PubMed  PubMed Central  Google Scholar 

  • San Luis VA, Btaiche IF (2007) Ursodiol in patients with parenteral nutrition-associated cholestasis. Ann Pharmacother 41(11):1867–1872

    Article  CAS  PubMed  Google Scholar 

  • Sasaki M, Nakanuma Y (2017) Bile acids and deregulated cholangiocyte autophagy in primary biliary cholangitis. Dig Dis 35(3):210–216

    Article  PubMed  Google Scholar 

  • Sasaki M, Sato Y, Nakanuma Y (2018) An impaired biliary bicarbonate umbrella may be involved in dysregulated autophagy in primary biliary cholangitis. Lab Investig 98(6):745–754

    Article  CAS  PubMed  Google Scholar 

  • Sato K, Meng F, Giang T, Glaser S, Alpini G (2018) Mechanisms of cholangiocyte responses to injury. Biochim Biophys Acta Mol basis Dis 1864(4 Pt B):1262–1269

    Article  CAS  PubMed  Google Scholar 

  • Sato K, Glaser S, Kennedy L, Liangpunsakul S, Meng F, Francis H et al (2019) Preclinical insights into cholangiopathies: disease modeling and emerging therapeutic targets. Expert Opin Ther Targets:1–12. https://doi.org/10.1080/14728222.2019.1608950

    Article  PubMed  PubMed Central  Google Scholar 

  • British Veterinary Association (2018) Saving bears from the bile farming trade. Vet Rec 183(19):586–587

    Article  Google Scholar 

  • Schoemaker MH, Conde de la Rosa L, Buist-Homan M, Vrenken TE, Havinga R, Poelstra K et al (2004) Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology 39(6):1563–1573

    Article  CAS  PubMed  Google Scholar 

  • Schteingart CD, Hofmann AF (1988) Synthesis of 24-nor-5 beta-cholan-23-oic acid derivatives: a convenient and efficient one-carbon degradation of the side chain of natural bile acids. J Lipid Res 29(10):1387–1395

    Article  CAS  PubMed  Google Scholar 

  • Sedki M, Levy C (2018) Update in the care and management of patients with primary sclerosing cholangitis. Curr Gastroenterol Rep 20(7):29

    Article  PubMed  Google Scholar 

  • Setchell KD, Rodrigues CM, Podda M, Crosignani A (1996) Metabolism of orally administered tauroursodeoxycholic acid in patients with primary biliary cirrhosis. Gut 38(3):439–446

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sharma R, Long A, Gilmer JF (2011) Advances in bile acid medicinal chemistry. Curr Med Chem 18(26):4029–4052

    Article  CAS  PubMed  Google Scholar 

  • Shoda M (1927) Uber die ursodesoxycholsaure aus barengallen und ihre physiologische wirkung. J Biochem 7:505–517

    Article  CAS  Google Scholar 

  • Sombetzki M, Fuchs CD, Fickert P, Osterreicher CH, Mueller M, Claudel T et al (2015) 24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis. J Hepatol 62(4):871–878

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Steinacher D, Claudel T, Trauner M (2017) Therapeutic mechanisms of bile acids and nor-ursodeoxycholic acid in non-alcoholic fatty liver disease. Dig Dis 35(3):282–287

    Article  PubMed  Google Scholar 

  • Stiehl A, Czygan P, Kommerell B, Weis HJ, Holtermuller KH (1978) Ursodeoxycholic acid versus chenodeoxycholic acid. Comparison of their effects on bile acid and bile lipid composition in patients with cholesterol gallstones. Gastroenterology 75(6):1016–1020

    Article  CAS  PubMed  Google Scholar 

  • Stokes CS, Gluud LL, Casper M, Lammert F (2014) Ursodeoxycholic acid and diets higher in fat prevent gallbladder stones during weight loss: a meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 12(7):1090–1100 e2. quiz e61

    Article  CAS  PubMed  Google Scholar 

  • Stravitz RT, Rao YP, Vlahcevic ZR, Gurley EC, Jarvis WD, Hylemon PB (1996) Hepatocellular protein kinase C activation by bile acids: implications for regulation of cholesterol 7 alpha-hydroxylase. Am J Phys 271(2 Pt 1):G293–G303

    CAS  Google Scholar 

  • Sundaram V, Bjornsson ES (2017) Drug-induced cholestasis. Hepatol Commun 1(8):726–735

    Article  PubMed  PubMed Central  Google Scholar 

  • Tabibian JH, Lindor KD (2014) Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?). Hepatology 60(3):785–788

    Article  CAS  PubMed  Google Scholar 

  • Tabibian JH, O’Hara SP, Trussoni CE, Tietz PS, Splinter PL, Mounajjed T et al (2016) Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. Hepatology 63(1):185–196

    Article  CAS  PubMed  Google Scholar 

  • Takikawa H, Sano N, Minagawa K, Yamanaka M (1992) Effects of ursodeoxycholate, its glucuronide and disulfate and beta-muricholate on biliary bicarbonate concentration and biliary lipid excretion. J Hepatol 15(1–2):77–84

    Article  CAS  PubMed  Google Scholar 

  • Tanaka H, Makino I (1992) Ursodeoxycholic acid-dependent activation of the glucocorticoid receptor. Biochem Biophys Res Commun 188(2):942–948

    Article  CAS  PubMed  Google Scholar 

  • Tang R, Wei Y, Li Y, Chen W, Chen H, Wang Q et al (2018a) Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut 67(3):534–541

    Article  CAS  PubMed  Google Scholar 

  • Tang Y, Blomenkamp KS, Fickert P, Trauner M, Teckman JH (2018b) NorUDCA promotes degradation of alpha1-antitrypsin mutant Z protein by inducing autophagy through AMPK/ULK1 pathway. PLoS One 13(8):e0200897

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Trauner M, Boyer JL (2003) Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 83(2):633–671

    Article  CAS  PubMed  Google Scholar 

  • Trauner M, Halilbasic E, Claudel T, Steinacher D, Fuchs C, Moustafa T et al (2015) Potential of nor-ursodeoxycholic acid in cholestatic and metabolic disorders. Dig Dis 33(3):433–439

    Article  PubMed  Google Scholar 

  • Trauner M, Fuchs CD, Halilbasic E, Paumgartner G (2017) New therapeutic concepts in bile acid transport and signaling for management of cholestasis. Hepatology 65(4):1393–1404

    Article  PubMed  Google Scholar 

  • Traussnigg S, Schattenberg JM, Demir M, Wiegand J, Geier A, Teuber G et al (2017) norUrsodeoxycholic acid (norUDCA) improves non-alcoholic fatty liver disease (NAFLD): results from a randomized placebo-controlled, double-blind phase IIa study. Hepatology 66(S1):106A

    Google Scholar 

  • Uriz M, Saez E, Prieto J, Medina JF, Banales JM (2011) Ursodeoxycholic acid is conjugated with taurine to promote secretin-stimulated biliary hydrocholeresis in the normal rat. PLoS One 6(12):e28717

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • van der Feen C, van der Doef HP, van der Ent CK, Houwen RH (2016) Ursodeoxycholic acid treatment is associated with improvement of liver stiffness in cystic fibrosis patients. J Cyst Fibros 15(6):834–838

    Article  PubMed  CAS  Google Scholar 

  • van Niekerk J, Kersten R, Beuers U (2018) Role of bile acids and the biliary HCO3(−) umbrella in the pathogenesis of primary biliary cholangitis. Clin Liver Dis 22(3):457–479

    Article  PubMed  Google Scholar 

  • Vang S, Longley K, Steer CJ, Low WC (2014) The unexpected uses of urso- and tauroursodeoxycholic acid in the treatment of non-liver diseases. Glob Adv Health Med 3(3):58–69

    Article  PubMed  PubMed Central  Google Scholar 

  • Wagner M, Trauner M (2016) Recent advances in understanding and managing cholestasis. F1000Res 5:705

    Article  CAS  Google Scholar 

  • Wagner M, Zollner G, Trauner M (2010) Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis. Semin Liver Dis 30(2):160–177

    Article  CAS  PubMed  Google Scholar 

  • Wahlstrom A (2019) Outside the liver box: the gut microbiota as pivotal modulator of liver diseases. Biochim Biophys Acta Mol basis Dis 1865(5):912–919

    Article  PubMed  CAS  Google Scholar 

  • Wiemuth D, Sahin H, Lefevre CM, Wasmuth HE, Grunder S (2013) Strong activation of bile acid-sensitive ion channel (BASIC) by ursodeoxycholic acid. Channels (Austin) 7(1):38–42

    Article  CAS  Google Scholar 

  • Wood AM, Livingston EG, Hughes BL, Kuller JA (2018) Intrahepatic cholestasis of pregnancy: a review of diagnosis and management. Obstet Gynecol Surv 73(2):103–109

    Article  PubMed  Google Scholar 

  • Woolbright BL, Jaeschke H (2016) Therapeutic targets for cholestatic liver injury. Expert Opin Ther Targets 20(4):463–475

    Article  CAS  PubMed  Google Scholar 

  • Xia X, Francis H, Glaser S, Alpini G, LeSage G (2006) Bile acid interactions with cholangiocytes. World J Gastroenterol 12(22):3553–3563

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yamanaka M, Oto M, Obata H, Shimizu M, Sugata F, Hatta Y et al (1976) The examination of the therapeutic efficacy of ursodeoxycholic acid on chronic hepatitis. A double blind study. Shindan Chiryo 64:2150–2157

    Google Scholar 

  • Yoon YB, Hagey LR, Hofmann AF, Gurantz D, Michelotti EL, Steinbach JH (1986) Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents. Gastroenterology 90(4):837–852

    Article  CAS  PubMed  Google Scholar 

  • Yoshikawa M, Tsujii T, Matsumura K, Yamao J, Matsumura Y, Kubo R et al (1992) Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 16(2):358–364

    Article  CAS  PubMed  Google Scholar 

  • Younossi Z, Tacke F, Arrese M, Sharma BC, Mostafa I, Bugianesi E et al (2018) Global perspectives on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Hepatology. https://doi.org/10.1002/hep.30251

    Article  PubMed  Google Scholar 

  • Zhou Y, Doyen R, Lichtenberger LM (2009) The role of membrane cholesterol in determining bile acid cytotoxicity and cytoprotection of ursodeoxycholic acid. Biochim Biophys Acta 1788(2):507–513

    Article  CAS  PubMed  Google Scholar 

Download references

Declaration of Interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Funding

Financial support and sponsorship: This article was partially supported by the Chilean government through the Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT 1119145 to M.A.) and the Comisión Nacional de Investigación Científica y Tecnológica (grant CONICYT PIA/Basal PFB12, Basal Centre for Excellence in Science and Technology to M.A.).

Author information

Authors and Affiliations

  1. Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile

    Daniel Cabrera, Juan Pablo Arab & Marco Arrese

  2. Departamento de Ciencias Químicas y Biológicas, Facultad de Salud, Universidad Bernardo O’Higgins, Santiago, Chile

    Daniel Cabrera

Authors
  1. Daniel Cabrera
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juan Pablo Arab
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marco Arrese
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marco Arrese .

Editor information

Editors and Affiliations

  1. University of Perugia, School of Medicine, Perugia, Italy

    Stefano Fiorucci

  2. S.C. Gastroenterologia, Azienda Ospedaliera di Perugia, Perugia, Italy

    Eleonora Distrutti

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Cabrera, D., Arab, J.P., Arrese, M. (2019). UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications. In: Fiorucci, S., Distrutti, E. (eds) Bile Acids and Their Receptors. Handbook of Experimental Pharmacology, vol 256. Springer, Cham. https://doi.org/10.1007/164_2019_241

Download citation

Publish with us

Policies and ethics

Search

Navigation